Immutep S.a.s.

This large, late-stage trial is testing whether adding a new immunotherapy drug called eftilagimod alfa (efti) to the current standard treatment helps people with advanced non-small cell lung cancer live longer. About 756 participants will be randomly assigned to receive either t…